| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Sales - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.658 | 41.357 | 57.552 |
| Total Income - EUR | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 4.658 | 41.357 | 57.552 |
| Total Expenses - EUR | 0 | 901 | 886 | 870 | 853 | 837 | 818 | 1.669 | 16.670 | 29.691 |
| Gross Profit/Loss - EUR | 0 | -901 | -886 | -870 | -853 | -837 | -818 | 2.990 | 24.688 | 27.861 |
| Net Profit/Loss - EUR | 0 | -901 | -886 | -870 | -853 | -837 | -818 | 2.244 | 24.274 | 26.135 |
| Employees | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 1 |
Check the financial reports for the company - Diatest Biosano-Med Srl
| 2015 | 2016 | 2017 | 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | |
|---|---|---|---|---|---|---|---|---|---|---|
| Fixed Assets | 0 | 171 | 168 | 165 | 162 | 159 | 155 | 0 | 0 | 62.627 |
| Current Assets | 45 | 265 | 260 | 256 | 251 | 246 | 240 | 3.563 | 27.722 | 15.576 |
| Inventories | 0 | 145 | 142 | 140 | 137 | 134 | 131 | 0 | 0 | 0 |
| Receivables | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 44 | 26.132 | 1.185 |
| Cash | 45 | 120 | 118 | 116 | 114 | 111 | 109 | 3.519 | 1.590 | 14.391 |
| Shareholders Funds | 45 | -857 | -842 | -827 | -811 | -795 | -778 | 2.285 | 26.552 | 52.538 |
| Social Capital | 45 | 45 | 44 | 43 | 42 | 41 | 40 | 41 | 40 | 40 |
| Debts | 0 | 1.293 | 1.271 | 1.247 | 1.223 | 1.200 | 1.173 | 1.278 | 1.170 | 25.666 |
| Income in Advance | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Exchange rate - RON | 4.9743 | 4.9465 | 4.9315 | 4.9468 | 4.8371 | 4.7454 | 4.6535 | 4.5681 | 4.4908 | 4.445 |
| Main CAEN | "8622 - 8622" | |||||||||
| CAEN Financial Year |
8622
|
|||||||||
Comments - Diatest Biosano-Med Srl